In T2D patients, the presence of the second-phase hyperinsulinemia, together with the flat post-peak activity of IRS2, contributes to the hyperactivity of aPKC in the liver of these patients (Figs. 5, 6). The gene discussed is IRS2; the disease is hyperinsulinism.